by NImmune Biopharma | May 17, 2023 | Press Release
Download Press Release Approvable population of ulcerative colitis (UC) patients for upcoming Phase 3 trials agreed upon with the U.S. Food and Drug Administration (FDA) Analysis of Phase 2 data using approvable UC patient population for Phase 3 demonstrated...
by NImmune Biopharma | May 3, 2023 | Press Release
Download Press Release Provides NImmune access to NIMML’s TITAN-X advanced computational modeling and A.I. platform to accelerate biomarker-driven clinical development of its LANCL immunoregulatory drug pipeline NImmune will commit up to $15 million in R&D funding...
by NImmune Biopharma | Mar 22, 2023 | Press Release
Download Press Release — Led by Dr. Bassaganya-Riera and a team of seasoned industry executives, NImmune is developing later-stage precision therapies addressing multiple autoimmune diseases, starting with Ulcerative Colitis (UC) and Crohn’s disease (CD) — NImmune’s...
